Global Gastroesophageal Reflux Disease Therapeutics Market Landscape: Trends and Market Share to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Gastroesophageal Reflux Disease Therapeutics Sector?
Over the past few years, the market size for therapeutics in gastroesophageal reflux disease has seen consistent growth. It is anticipated to increase from $5.93 billion in 2024 to $6.08 billion in 2025, experiencing a compound annual growth rate (CAGR) of 2.5%. Factors such as lifestyle and dietary changes, an aging populace, heightened awareness and diagnosis, prevalent stressful lifestyles, and a surge in obesity rates are all contributing to the growth seen during this historic period.
Anticipated to witness robust growth in the coming years, the therapeutics market for gastroesophageal reflux disease is predicted to expand to “$7.74 billion in 2029 with a compound annual growth rate (CAGR) of 6.2%. This projected growth trajectory during the forecast period can be associated with the rising demand for innovative therapies, aging population, tailored medication strategies, emphasis on non-drug interventions, and the advent of biological and pioneering therapies. Some major trends to watch out for during this period encompass alternative therapies, mind-body practices, extensive gut health research, the emergence of patient-oriented care models, GERD awareness through targeted marketing, and the incorporation of digital health technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp
What Forces Are Driving The Growth Of The Gastroesophageal Reflux Disease Therapeutics Market?
The anticipated increase in cases of gastroesophageal reflux disease (GERD) is projected to fuel the expansion of the GERD therapeutics market. GERD is a persistent ailment marked by the reverse flow of stomach acid into the esophagus, leading to symptoms like heartburn, regurgitation, and potential complications. GERD therapeutics are designed to manage these symptoms, neutralizing the gastric pH, reducing inflammation, and enhancing the function of the esophagus. For instance, a September 2022 article by WebMed, a US-based online health information publisher, reported that over 60 million American adults experience heartburn at least once a month, and over 15 million have daily occurrences. Further data shared by the National Library of Medicine in July 2022, a US federal medical library, stated that GERD is one of the most commonly diagnosed gastrointestinal disorders in the US, with a 20% prevalence. This scenario leads to significant economic implications due to the direct and indirect costs involved and negatively affects the quality of life. Hence, the rising prevalence of GERD is expected to catalyze the expansion of the GERD therapeutics market.
The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
Which Emerging Trends And Strategic Shifts Are Shaping The Gastroesophageal Reflux Disease Therapeutics Market?
One conspicuous trend in the gastroesophageal reflux disease therapeutics market is the importance of product innovations. To stay competitive in the market, major companies are focusing on the development of novel treatments. For example, Phathom Pharmaceuticals, a biopharmaceutical enterprise based in the US, introduced VOQUEZNA (vonoprazan) in the market in November 2023. This medication is a potassium-competitive acid blocker, approved for treating all grades of erosive esophagitis and relief from heartburn in both erosive and non-erosive GERD. Clinical studies revealed impressive results, with a 93% healing rate observed in patients who took a 20 mg dosage, which is higher than the 85% healing rate observed in patients using the conventional proton pump inhibitor, lansoprazole.
Which Companies Currently Dominate The Competitive Landscape In The Gastroesophageal Reflux Disease Therapeutics Industry?
Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited
Which Geographic Regions Are Driving Demand In The Gastroesophageal Reflux Disease Therapeutics Market?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12058&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
